Recent Investment Analysts’ Ratings Changes for Synopsys (SNPS)

A number of research firms have changed their ratings and price targets for Synopsys (NASDAQ: SNPS):

• 10/12/2026 – Synopsys had its price target raised by Needham & Company LLC from $580.00 to $620.00. They now have a “buy” rating on the stock.
• 10/2/2026 – Synopsys was upgraded by Zacks Research from “hold” to “strong-buy”.
• 10/1/2026 – Synopsys had its “buy” rating reaffirmed by Deutsche Bank Aktiengesellschaft. They now have a $640.00 price target on the stock, up from $590.00.
• 10/1/2026 – Synopsys had its price target raised by KeyCorp from $600.00 to $605.00. They now have an “overweight” rating on the stock.
• 10/1/2026 – Synopsys had its price target raised by Wells Fargo & Company from $475.00 to $540.00. They now have an “overweight” rating on the stock.
• 10/1/2026 – Synopsys had its price target raised by Bank of America Corporation from $500.00 to $600.00.
• 10/1/2026 – Synopsys had its price target raised by BNP Paribas Exane from $420.00 to $475.00. They now have a “neutral” rating on the stock.
• 10/1/2026 – Synopsys had its price target raised by Rosenblatt Securities from $575.00 to $620.00. They now have a “buy” rating on the stock.
• 9/25/2026 – Synopsys was upgraded by Roth Capital to “buy”.
• 9/25/2026 – Synopsys was downgraded by HSBC Holdings plc from “buy” to “reduce”.
• 9/25/2026 – Synopsys was downgraded by KeyCorp from “overweight” to “strong sell”.
• 9/25/2026 – Synopsys is now covered by Sanford C. Bernstein. They set an “outperform” rating on the stock.
• 9/25/2026 – Synopsys is now covered by Barclays PLC. They set an “overweight” rating on the stock.
• 9/25/2026 – Synopsys was upgraded by HSBC Holdings plc from “hold” to “buy”. They now have a $700.00 price target on the stock, up from $490.00.
• 9/24/2026 – Synopsys was upgraded by BNP Paribas Exane from “underperform” to “neutral”. They now have a $420.00 price target on the stock, down from $450.00.
• 9/23/2026 – Synopsys had its price target lowered by Rothschild & Co Redburn from $560.00 to $550.00. They now have a “buy” rating on the stock.
• 9/11/2026 – Synopsys was downgraded by Weiss Ratings from “hold (c)” to “hold (c-)”.
• 9/10/2026 – Synopsys was upgraded by Wells Fargo & Company from “equal weight” to “overweight”. They now have a $475.00 price target on the stock, up from $450.00.
• 8/27/2026 – Synopsys was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
• 8/27/2026 – Synopsys was given a new $570.00 price target by UBS Group AG.
• 8/27/2026 – Synopsys had its price target lowered by Mizuho from $600.00 to $550.00. They now have an “outperform” rating on the stock.
• 8/27/2026 – Synopsys was upgraded by Robert W. Baird from “neutral” to “outperform”. They now have a $560.00 price target on the stock, up from $558.00.
• 8/27/2026 – Synopsys had its price target lowered by JPMorgan Chase & Co. from $650.00 to $600.00.
• 8/27/2026 – Synopsys had its “buy” rating reaffirmed by Benchmark Co.. They now have a $570.00 price target on the stock.
• 8/27/2026 – Synopsys had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $580.00 price target on the stock.
• 8/25/2026 – Synopsys had its “buy” rating reaffirmed by Rosenblatt Securities. They now have a $575.00 price target on the stock.
• 8/21/2026 – Synopsys was downgraded by Zacks Research from “strong-buy” to “hold”.
• 8/19/2026 – Synopsys had its “buy” rating reaffirmed by Benchmark Co..
• 8/19/2026 – Synopsys had its price target lowered by Morgan Stanley from $525.00 to $500.00. They now have an “equal weight” rating on the stock.
• 8/19/2026 – Synopsys had its “overweight” rating reaffirmed by KeyCorp.

Insider Transactions at Synopsys

In other news, insider Aart de Geus sold 24,641 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $419.44, for a total value of $10,335,421.04. Following the transaction, the insider directly owned 120,443 shares in the company, valued at $50,518,611.92. This trade represents a 16.98% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Sassine Ghazi sold 14,604 shares of Synopsys stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $374.88, for a total value of $5,474,747.52. Following the completion of the transaction, the chief executive officer directly owned 76,865 shares in the company, valued at $28,815,151.20. This represents a 15.97% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 102,559 shares of company stock worth $44,607,141 in the last three months. 0.56% of the stock is currently owned by insiders.

Synopsys, Inc is a technology company that develops electronic design automation (EDA) software, semiconductor intellectual property (IP), and software tools used to design, verify, and manufacture advanced electronic systems. Its solutions support the development of semiconductors, systems-on-chip, and electronic products across the design cycle, from initial specification and architecture through testing and production.

The company’s offerings include digital and custom integrated-circuit design tools, simulation and verification software, physical design and signoff products, and semiconductor IP such as processor cores, interface technologies, and foundational components.